XML 114 R78.htm IDEA: XBRL DOCUMENT v3.20.1
Investments in Variable Interest Entities (Details) - USD ($)
$ in Millions
1 Months Ended
May 31, 2018
Oct. 31, 2017
Mar. 31, 2020
Dec. 31, 2019
Variable Interest Entity [Line Items]        
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities     $ 22.7 $ 22.7
Neurimmune        
Variable Interest Entity [Line Items]        
Payments to Noncontrolling Interests $ 50.0 $ 150.0    
Reduction in royalty rate payable on commercial sales   15.00%    
Additional reduction in royalty rate payable on commercial sales 5.00%      
Regulatory Milestones [Member] | Neurimmune        
Variable Interest Entity [Line Items]        
Potential Future Milestone Payments Commitment To Third Party Approximately       75.0
Regulatory Approval Milestone [Member] | Neurimmune        
Variable Interest Entity [Line Items]        
Potential Future Milestone Payments Commitment To Third Party Approximately       $ 100.0